logo
Dangerous AI therapy-bots are running amok. Congress must act.

Dangerous AI therapy-bots are running amok. Congress must act.

The Hilla day ago

A national crisis is unfolding in plain sight. Earlier this month, the Federal Trade Commission received a formal complaint about artificial intelligence therapist bots posing as licensed professionals. Days later, New Jersey moved to fine developers for deploying such bots.
But one state can't fix a federal failure.
These AI systems are already endangering public health — offering false assurances, bad advice and fake credentials — while hiding behind regulatory loopholes.
Unless Congress acts now to empower federal agencies and establish clear rules, we'll be left with a dangerous, fragmented patchwork of state responses and increasingly serious mental health consequences around the country.
The threat is real and immediate. One Instagram bot assured a teenage user it held a therapy license, listing a fake number. According to the San Francisco Standard, a Character.AI bot used a real Maryland counselor's license ID. Others reportedly invented credentials entirely. These bots sound like real therapists, and vulnerable users often believe them.
It's not just about stolen credentials. These bots are giving dangerous advice.
In 2023, NPR reported that the National Eating Disorders Association replaced its human hotline staff with an AI bot, only to take it offline after it encouraged anorexic users to reduce calories and measure their fat.
This month, Time reported that psychiatrist Andrew Clark, posing as a troubled teen, interacted with the most popular AI therapist bots. Nearly a third gave responses encouraging self-harm or violence.
A recently published Stanford study confirmed how bad it can get: Leading AI chatbots consistently reinforced delusional or conspiratorial thinking during simulated therapy sessions.
Instead of challenging distorted beliefs — a cornerstone of clinical therapy — the bots often validated them. In crisis scenarios, they failed to recognize red flags or offer safe responses. This is not just a technical failure; it's a public health risk masquerading as mental health support.
AI does have real potential to expand access to mental health resources, particularly in underserved communities.
A recent NEJM-AI study found that a highly structured, human-supervised chatbot was associated with reduced depression and anxiety symptoms and triggered live crisis alerts when needed. But that success was built on clear limits, human oversight and clinical responsibility. Today's popular AI 'therapists' offer none of that.
The regulatory questions are clear. Food and Drug Administration 'software as a medical device' rules don't apply if bots don't claim to 'treat disease'. So they label themselves as 'wellness' tools and avoid any scrutiny.
The FTC can intervene only after harm has occurred. And no existing frameworks meaningfully address the platforms hosting the bots or the fact that anyone can launch one overnight with no oversight.
We cannot leave this to the states. While New Jersey's bill is a step in the right direction, relying on individual states to police AI therapist bots invites inconsistency, confusion, and exploitation.
A user harmed in New Jersey could be exposed to identical risks coming from Texas or Florida without any recourse. A fragmented legal landscape won't stop a digital tool that crosses state lines instantly.
We need federal action now. Congress must direct the FDA to require pre-market clearance for all AI mental health tools that perform diagnosis, therapy or crisis intervention, regardless of how they are labeled. Second, the FTC must be given clear authority to act proactively against deceptive AI-based health tools, including holding platforms accountable for negligently hosting such unsafe bots.
Third, Congress must pass national legislation to criminalize impersonation of licensed health professionals by AI systems, with penalties for their developers and disseminators, and require AI therapy products to display disclaimers and crisis warnings, as well as implement meaningful human oversight.
Finally, we need a public education campaign to help users — especially teens — understand the limits of AI and to recognize when they're being misled. This isn't just about regulation. Ensuring safety means equipping people to make informed choices in a rapidly changing digital landscape.
The promise of AI for mental health care is real, but so is the danger. Without federal action, the market will continue to be flooded by unlicensed, unregulated bots that impersonate clinicians and cause real harm.
Congress, regulators and public health leaders: Act now. Don't wait for more teenagers in crisis to be harmed by AI. Don't leave our safety to the states. And don't assume the tech industry will save us.
Without leadership from Washington, a national tragedy may only be a few keystrokes away.
Shlomo Engelson Argamon is the associate provost for Artificial Intelligence at Touro University.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Microsoft AI CEO Mustafa Suleyman: AI can provide complex medical support, diagnoses
Microsoft AI CEO Mustafa Suleyman: AI can provide complex medical support, diagnoses

Yahoo

timean hour ago

  • Yahoo

Microsoft AI CEO Mustafa Suleyman: AI can provide complex medical support, diagnoses

Microsoft says its AI can now outperform doctors in diagnosing complex medical cases. "We already have 50 million health-related queries per day coming through Copilot and Bing," Microsoft AI CEO Mustafa Suleyman said on Yahoo Finance's Opening Bid. "Our goal is to provide the most high quality, most accurate, and ultimately the cheapest health advice and support." The six-year relationship between Microsoft (MSFT) and Sam Altman's OpenAI ( is widely seen as one of the most successful tie-ups in recent memory. Microsoft has invested close to $14 billion in the ChatGPT maker, gaining access to its models. OpenAI has leveraged the computing power of Microsoft to feed its ever-more-powerful models. OpenAI has gone on to raise billions, with its last round in March valuing it at $300 billion. The company's valuation has since climbed to $325 billion, according to Yahoo Finance private company data. Since disclosing an initial $1 billion investment into OpenAI on July 22, 2019, Microsoft shares are up 263%. The S&P 500 has gained 107%. In new research, the tech giant said the Microsoft AI Diagnostics Orchestrator (MAI-Dx0) can correctly diagnose up to 85% of the New England Journal of Medicine case proceedings. It's a rate more than four times higher than a group of experienced physicians. The best-performing MAI-DxO was paired with OpenAI's o3 model. Users shouldn't say goodbye to their doctors just yet. "Your physician will be there to make the right judgement call at the right time, to plan treatment after diagnosis, and to oversee and hold the AI accountable," Suleyman said. Recently, the relationship between Microsoft and OpenAI has begun to sour. OpenAI wants Microsoft to ease up its hold on its AI offerings, and allow for its conversion to a for-profit company. The pact between the two is slated to last until 2030 but could end earlier if OpenAI's board declares it has developed artificial general intelligence (AGI). Suleyman downplayed any tension in the partnership. "The relationship's in pretty good shape," he said. "It's one of the best technology partnerships there has been and it will continue for at least another five years, hopefully many decades after that." He acknowledged ongoing discussions around the agreement, describing it as a "very complicated contract," but described them as a part of healthy, evolving alliance and one "that's definitely going to continue." Suleyman is one of the most prominent names in artificial intelligence. He was one of the co-founders of DeepMind, which Google acquired in 2014. He then became a vice president at Google for several years before leaving in 2022 to found AI startup Inflection. Suleyman joined Microsoft in his current role in March 2024 after securing a licensing deal for Inflection's core technology. As part of the deal, Suleyman, his co-founder at Inflection, Karén Simonyan, and a majority of its employees joined Microsoft. At Microsoft, Suleyman now oversees all of its consumer AI products, including the Copilot app, Bing, MSN, and the Edge browser. Brian Sozzi is Yahoo Finance's Executive Editor and a member of Yahoo Finance's editorial leadership team. Follow Sozzi on X @BrianSozzi, Instagram, and LinkedIn. Tips on stories? Email Francisco Velasquez is a reporter for Yahoo Finance. He can be reached on X and LinkedIn.

Donald Trump's Tax Bill To Undergo Major Change: What To Know
Donald Trump's Tax Bill To Undergo Major Change: What To Know

Newsweek

timean hour ago

  • Newsweek

Donald Trump's Tax Bill To Undergo Major Change: What To Know

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Republican Senator Rick Scott of Florida unveiled an amendment to President Donald Trump's One Big Beautiful Bill Act that would further shrink Medicaid spending. Roughly 71 million people are enrolled in Medicaid, a government health insurance program that provides free or low-cost coverage to eligible low-income individuals and families, including children, pregnant women, seniors and people with disabilities. Newsweek has contacted Scott's office for comment via email outside regular working hours. Why It Matters Republicans in Congress are seeking to cut Medicaid spending in order to pay for the extension of Trump's Tax Cuts and Jobs Act 2017, which is set to expire at the end of this year. A new analysis by the Congressional Budget Office found that the latest version of Trump's bill would result in 11.8 million more Americans being uninsured by 2034 and would cut more than $1.1 trillion from Medicaid, Medicare and Obamacare—more than $1 trillion of which would come from Medicaid alone. Republicans have argued that their changes would incentivize work and prevent fraud. A Medicaid accepted here sign in Kokomo, Indiana, in September 2019. A Medicaid accepted here sign in Kokomo, Indiana, in September 2019. GETTY What To Know The amendment would block new enrollees in Medicaid expansion states from receiving the enhanced 9-to-1 Federal Medical Assistance Percentage (FMAP) if they are able-bodied and have no dependent children. Current Medicaid enrollees in expansion states would retain the 9-to-1 rate, even if they leave the program temporarily to work. The lower FMAP rate for new enrollees would take effect in 2031. According to a report by The Hill, the amendment, if passed, would save an additional $313 billion in federal spending. It is co-sponsored by GOP Senators Cynthia Lummis of Wyoming, Ron Johnson of Wisconsin, Mike Lee of Utah and Finance Chair Mike Crapo of Idaho. The amendment has also won the support of other Republicans, with Florida Representative Randy Fine saying on X, formerly Twitter, that he is "all in." I'm all in. Florida has proven Obamacare Medicaid Expansion is a scam. With th is amendment, Florida taxpayers will get less ripped off by Blue States handing out free healthcare to illegals and twenty-somethings too busy protesting to get jobs. Well done, @SenRickScott! — Congressman Randy Fine (@RepFine) June 29, 2025 What People Are Saying Senator Rick Scott, a Florida Republican, on X, formerly Twitter, on June 29: "My proposal to fix FMAP will make the Big Beautiful Bill even more aligned with President Trump's goal to balance the budget, grow the economy, and put Americans first. "We cannot allow Dem-led blue states to use YOUR tax dollars to give illegal aliens Medicaid benefits, exploit this safety net, and jeopardize help for those who truly need it." Senate Majority Leader John Thune, a South Dakota Republican, told reporters on Sunday, per Semafor: "We think it's a really good policy, and I think a lot of us are going to be supporting it. It's great policy and something that's there's a high level of interest in our conference of making it part of the final bill." House Minority Leader Hakeem Jeffries, a New York Democrat, on X: "Republicans are jamming an insane and destructive bill down the throats of the American people in the dead of night. It's the largest cut to Medicaid in American history. The massive tax breaks for billionaires will add trillions to our national debt. Keep the pressure on." What Happens Next The Senate voted 51-49 late Saturday to proceed with the bill, teeing off the next steps toward passing it, likely this week. It would then head back to the House for a final vote before being signed into law by the president.

industryGENOME Unveils Groundbreaking Clinical Trial PAO Market Map Report, Powered by AI-Assisted Market Intelligence
industryGENOME Unveils Groundbreaking Clinical Trial PAO Market Map Report, Powered by AI-Assisted Market Intelligence

Business Wire

timean hour ago

  • Business Wire

industryGENOME Unveils Groundbreaking Clinical Trial PAO Market Map Report, Powered by AI-Assisted Market Intelligence

TAMPA, Fla.--(BUSINESS WIRE)--industryGENOME, a cutting-edge analytics firm specializing in granular precision insights, has released its first-ever Clinical Trial Patient Access Organization (PAO) Market Map Report, developed in collaboration with WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, and Crosstree. This report offers an unparalleled bottom-up analysis of the PAO sector, using AI-powered classification models to predict private company revenue and stratify market estimates across geographies, subsidiaries, and specialized capabilities. Transforming Industry Analysis with AI-Assisted Precision Leveraging its proprietary Industry Capabilities Classification System (ICCS ®), industryGENOME provides a standardized and globally applicable framework for categorizing businesses. The ICCS ® methodology enhances financial analysis, investment decision-making, and strategy development across the life sciences and healthcare industries. The report was developed in close collaboration with WCG, which played a pivotal role in identifying global industry participants to ensure the most comprehensive market representation. Crosstree assisted industryGENOME in industry classification quality assurance and predictive modeling, enhancing the precision of market insights. 'This report is the most sophisticated analysis of the clinical trial PAO sector to date, ' said Shane Senior, Managing Director at Crosstree. 'industryGENOME's AI-driven predictive engines achieve 85% classification accuracy, surpassing human classifiers, and ensuring the most precise industry intelligence for investors and market participants. The ability to scale this precision across large data sets is unprecedented.' Key Findings from the Clinical Trial PAO Market Map Report Total Market Revenue: $14.95 billion Industry Participants: Over 3,000 global Patient Access Organizations with detailed company profiles for each Industry Stratification: Freestanding, Mobile, Virtual, Provider Embedded, and Service Embedded Sites Top Industry Players: Velocity, IQVIA, PPD, AES, CenExel Clinical Research, ERG, Javara Advanced Market Mapping: AI-assisted data collection and synthesis for high-fidelity revenue estimates allowing for 'sum-of-the-parts' bottom-up market sizing Geo-Stratification Analysis: The United States leads with $10.6 billion in revenue, followed by the UK, Germany, and Australia Why This Report Sets a New Standard industryGENOME's bottom-up methodology, empowered by machine learning and predictive analytics, provides unprecedented insights into the PAO sector. The firm's mapped markets process, which identifies, collects, and analyzes micro-industry data, ensures highly precise revenue estimates, critical for investors, procurement specialists, and drug developers seeking strategic market positioning. Access the Report Today To access the Clinical Trial PAO Market Map Report, visit or contact Jordan Schiding at About industryGENOME industryGENOME is a market intelligence platform for the Health Sciences industry that continuously collects and analyzes millions of data points on pharma services companies, investors, deals, valuations, research, conferences, and news. It produces bottom-up market research reports and company profiles by combining AI with the expertise of industry investment professionals. The platform is distinguished by a proprietary, highly granular taxonomy that categorizes industry participant capabilities through defined relationships. This classification system delivers clean, precise, and actionable insights on the Health Sciences market. Using AI technologies—including natural language processing, machine translation, and supervised machine learning—industryGENOME classifies and curates data. In partnership with Crosstree, the platform trains its classification algorithm for accuracy and precision. Together, they are mapping the Health Sciences market one company at a time to deliver detailed, bottom-up industry segment insights. Learn more at About Crosstree Crosstree is a distinguished boutique investment banking firm focused exclusively on the needs of middle-market companies within three subsectors of the life sciences and healthcare industries: pharmaceutical services, diagnostics and tools, and digital health. Since 2004, Crosstree has advised on more completed transactions in these collective subsectors than any other investment bank. The firm provides clients a full suite of advisory and capital raising services, including both buy-and sell-side mergers and acquisitions advisory, private capital raising, strategic advisory, and valuations. Crosstree's narrow industry focus provides clients the expertise common of a bulge-bracket investment banking firm to middle-market companies and investors, with unparalleled industry insights, well-established strategic relationships across the globe and superior access to capital markets. From our offices in Tampa, Florida, Crosstree has advised clients throughout North America, Europe, India, China, Latin America, and Australia on transactions ranging from $25 million to more than $1 billion. About WCG WCG is at the forefront of accelerating clinical research worldwide, serving as the trusted and preferred partner to biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and site partners. Offering a unique combination of expertise, next-generation data and insights, and tech-enabled solutions, WCG reduces complexity and optimizes study operations and outcomes while maintaining the highest standards of human participant protection. For more than 55 years, WCG has maintained a relentless commitment to efficiency, safety, and impact, empowering clinical trials to deliver life-improving therapies swiftly. For more information, please visit or follow us on LinkedIn or X @WCGClinical.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store